Skip to main content
STADA Arzneimittel AG logo

STADA Arzneimittel AG — Investor Relations & Filings

Ticker · SAZ ISIN · DE0007251803 LEI · 529900FMTTLMH0P0DL10 HM Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2018-03-08 Earnings Release
Country DE Germany
Listing HM SAZ

About STADA Arzneimittel AG

https://www.stada.com/

STADA Arzneimittel AG is a pharmaceutical company that operates on a three-pillar strategy consisting of generics, consumer healthcare products, and specialty pharmaceuticals. The company is a leading manufacturer of affordable generic medicines, which have been a core part of its business since its founding. In the consumer healthcare segment, STADA markets a wide portfolio of over-the-counter (OTC) products and well-known brands. The specialty pharmaceuticals division focuses on developing and marketing value-added medicines, including an expanding portfolio of biosimilars for therapeutic areas such as oncology, immunology, and bone health.

Recent filings

Filing Released Lang Actions
STADA records positive business development in 2017
Earnings Release Classification · 100% confidence The document is titled 'STADA records positive business development in 2017' and contains extensive tables detailing 'STADA Group key figures' for the full year 2017 compared to 2016, including sales, EBITDA, net income, and EPS. It also breaks down performance by segment (Generics and Branded Products) and provides a detailed outlook for 2018 and 2019. This structure, focusing on comprehensive annual financial performance, key metrics, segment analysis, and future guidance, strongly indicates a full-year financial report. Since the document is a detailed report covering the entire fiscal year (2017) and includes comprehensive financial tables, it aligns best with the definition of an Annual Report (10-K), even though it is presented as a news release/DGAP announcement. The length (nearly 20,000 characters) confirms it is not a brief announcement (RPA/RNS) but the substance of the annual results. FY 2017
2018-03-08 English
STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a dividend in the amount of EUR0.11 per share
Notice of Dividend Amount Classification · 100% confidence The document explicitly states that the Executive Board and Supervisory Board resolved to propose a dividend of EUR0.11 per share to the General Meeting. This action directly relates to the distribution of profits to shareholders. The filing type definition for 'Notice of Dividend Amount (Code: DIV)' covers announcements of dividend amounts and details for shareholders. Although it mentions the publication of annual financial statements, the primary focus and headline of this ad-hoc announcement is the dividend proposal.
2018-03-08 English
Annual financial report 2017
Annual Report Classification · 100% confidence The document contains a comprehensive table of contents, a letter to shareholders, a combined management report, consolidated financial statements, and an independent auditor's report for the fiscal year 2017. It covers the full scope of company activity and financial performance, which is characteristic of an Annual Report (10-K). FY 2017
2018-03-08 English
Annual financial report 2017
Annual Report Classification · 100% confidence The document contains a comprehensive table of contents, a letter to shareholders, a combined management report, consolidated financial statements, and an independent auditor's report for the fiscal year 2017. It covers the full scope of company activity and financial performance, which is characteristic of an Annual Report (10-K). FY 2017
2018-03-08 German
STADA Arzneimittel AG: EMA started the evaluation of resubmitted marketing authorisation application for biosimilar pegfilgrastim
Legal Proceedings Report Classification · 99% confidence The document is a 'DGAP-News' release from STADA Arzneimittel AG dated March 2, 2018. It announces that the EMA has started the evaluation of a resubmitted marketing authorisation application for a biosimilar drug. This type of announcement, which communicates a specific operational or regulatory update that is not a full financial report (like 10-K or IR) or a standard earnings release (ER), fits best under the general 'Regulatory Filings' or 'Miscellaneous' category. Since the core content is an update on a regulatory submission process (EMA evaluation), and it is not a specific financial report, dividend notice, or management change, the most appropriate fallback category is Regulatory Filings (RNS), as it is a general regulatory announcement disseminated via DGAP.
2018-03-02 English
Report Publication Announcement 2018
Report Publication Announcement Classification · 100% confidence The document is titled "Preliminary announcement of the publication of quarterly reports and quarterly/interim statements." It explicitly states that it is a preliminary announcement regarding the disclosure of financial statements for the second half of the year, providing future disclosure dates and links to where the actual reports will be available. According to Rule 2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of a report, rather than being the report itself, should be classified as a Report Publication Announcement (RPA). The document length (1507 chars) supports this interpretation.
2018-02-26 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.